Search results
Virologist
- Harold Varmus (born December 18, 1939, Oceanside, New York, U.S.) is an American virologist and cowinner (with J. Michael Bishop) of the Nobel Prize for Physiology or Medicine in 1989 for his work on the origins of cancer.
www.britannica.com › biography › Harold-Varmus
People also ask
What did Harold Varmus discover?
What did Dr Varmus do for a living?
Who is Harold Varmus?
When did Dr Varmus resign from NIH?
Apr 12, 2024 · Harold Varmus, American virologist and cowinner (with J. Michael Bishop) of the Nobel Prize for Physiology or Medicine in 1989 for his work on the origins of cancer. He later served as president (2000–10) of Memorial Sloan Kettering Cancer Center in New York City.
- The Editors of Encyclopaedia Britannica
Varmus has criticized the high cost of many modern cancer drugs, which create barriers to treatment. He advocates for the genetic testing of cancers as a routine reimbursed procedure, and for wider use of the information that genetic testing of cancer can provide.
Oct 22, 2015 · Dr. Varmus’s scientific work before, during, and after his NIH Directorship has also included studies of retroviral replication; the development of mouse models of cancers; the discovery of the first mammalian Wnt genes; investigations of hepatitis B virus replication; and studies of the mechanisms of oncogene actions.
Biographical. I was born in the shadow of World War II, on December 18, 1939, on the south shore of Long Island, a product of the early twentieth century emigration of Eastern European Jewry to New York City and its environs. My father’s father, Jacob Varmus, left a village of uncertain name near Warsaw just after the turn of the century to ...
Dr. Varmus ran the Memorial Sloan-Kettering Cancer Center in New York City from 2000 to 2010, as President and Chief Executive Officer. He was then appointed Director of the National Cancer Institute .
We would like to show you a description here but the site won’t allow us.
Over his almost 50-year career, Varmus has seen the field of cancer genetics move from the stuff of laboratory experiments to become the cornerstone of cancer treatment. But there’s much left to learn and, as Varmus points out, the field’s most transformative discoveries still mostly benefit only the fraction of patients treated at academic ...
